Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3) ≥ 50~* Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer~* Prior chemotherapy is permitted with no limit on the number of prior regimens~* Two weeks or more have elapsed since last chemotherapy or radiation treatment~* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2~* Is female, ≥ 18 yrs of age~* Protocol defined appropriate laboratory values~* Negative pregnancy test within 7 calendar days prior to registration~* Has signed a patient informed consent~Exclusion Criteria:~* Had prior treatment with ixabepilone or other epothilones~* Has HER2+ disease~* Has a known, prior, severe (National Cancer Institute Common Terminology Criteria Adverse Events \[NCI CTCAE\] Grade 3-4) history of hypersensitivity reaction to a drug formulated in Cremophor ® EL (polyoxyethylated castor oil)~* Is receiving concurrent immunotherapy, hormonal therapy or radiation therapy~* Is receiving concurrent investigational therapy or has received such therapy within the past 30 days~* Has peripheral neuropathy \> Grade 1~* Has evidence of central nervous system (CNS) involvement requiring radiation or steroid treatment. Participants with stable brain metastases who are off steroids at least 2 weeks are eligible~* Is pregnant or breast feeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): ixabepilone 16 mg/m\^2 weekly for 3 weeks followed by 1 week rest
- Arm 2 (Type: ACTIVE_COMPARATOR): ixabepilone 40 mg/m\^2 every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).